Ra Eeles

List of Publications by Citations

178 papers	18,522 citations	66 h-index	135 g-index
202 ext. papers	23,117 ext. citations	10.9 avg, IF	5.53 L-index

#	Paper	IF	Citations
178	DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer. *New England Journal of Medicine*, **2015**, 373, 1697-708	59.2	1345
177	Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers. *JAMA - Journal of the American Medical Association*, **2017**, 317, 2402-2416	27.4	1140
176	Low-penetrance susceptibility to breast cancer due to CHEK2(*)1100delC in noncarriers of BRCA1 or BRCA2 mutations. *Nature Genetics*, **2002**, 31, 55-9	36.3	863
175	The evolutionary history of lethal metastatic prostate cancer. *Nature*, **2015**, 520, 353-357	50.4	857
174	Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer. *New England Journal of Medicine*, **2016**, 375, 443-53	59.2	791
173	Multiple newly identified loci associated with prostate cancer susceptibility. *Nature Genetics*, **2008**, 40, 316-21	36.3	722
172	REVEL: An Ensemble Method for Predicting the Pathogenicity of Rare Missense Variants. *American Journal of Human Genetics*, **2016**, 99, 877-885	11	722
171	Mutation spectrum and genotype-phenotype analyses in Cowden disease and Bannayan-Zonana syndrome, two hamartoma syndromes with germline PTEN mutation. *Human Molecular Genetics*, **1998**, 7, 507-15	5.6	458
170	Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer. *Journal of Clinical Oncology*, **2013**, 31, 1748-57	2.2	440
169	Identification of 23 new prostate cancer susceptibility loci using the iCOGS custom genotyping array. *Nature Genetics*, **2013**, 45, 385-91, 391e1-2	36.3	413
168	Identification of seven new prostate cancer susceptibility loci through a genome-wide association study. *Nature Genetics*, **2009**, 41, 1116-21	36.3	360
167	Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci. *Nature Genetics*, **2018**, 50, 928-936	36.3	340
166	A meta-analysis of 87,040 individuals identifies 23 new susceptibility loci for prostate cancer. *Nature Genetics*, **2014**, 46, 1103-9	36.3	331
165	Spatial genomic heterogeneity within localized, multifocal prostate cancer. *Nature Genetics*, **2015**, 47, 736-45	36.3	306
164	Two percent of men with early-onset prostate cancer harbor germline mutations in the BRCA2 gene. *American Journal of Human Genetics*, **2003**, 72, 1-12	11	293
163	Analysis of the genetic phylogeny of multifocal prostate cancer identifies multiple independent clonal expansions in neoplastic and morphologically normal prostate tissue. *Nature Genetics*, **2015**, 47, 367-372	36.3	292
162	Association of type and location of BRCA1 and BRCA2 mutations with risk of breast and ovarian cancer. *JAMA - Journal of the American Medical Association*, **2015**, 313, 1347-61	27.4	286

161	Prevention and early detection of prostate cancer. *Lancet Oncology, The*, **2014**, 15, e484-92	21.7	277
160	Multiple loci on 8q24 associated with prostate cancer susceptibility. *Nature Genetics*, **2009**, 41, 1058-60	36.3	252
159	BRCA2 is a moderate penetrance gene contributing to young-onset prostate cancer: implications for genetic testing in prostate cancer patients. *British Journal of Cancer*, **2011**, 105, 1230-4	8.7	249
158	Tumour genomic and microenvironmental heterogeneity for integrated prediction of 5-year biochemical recurrence of prostate cancer: a retrospective cohort study. *Lancet Oncology, The*, **2014**, 15, 1521-1532	21.7	218
157	A germline mutation in the androgen receptor gene in two brothers with breast cancer and Reifenstein syndrome. *Nature Genetics*, **1992**, 2, 132-4	36.3	215
156	Germline BRCA1 mutations increase prostate cancer risk. *British Journal of Cancer*, **2012**, 106, 1697-701	8.7	203
155	Effect of BRCA Mutations on Metastatic Relapse and Cause-specific Survival After Radical Treatment for Localised Prostate Cancer. *European Urology*, **2015**, 68, 186-93	10.2	192
154	Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer. *Nature Genetics*, **2017**, 49, 680-691	36.3	190
153	Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer. *Nature Genetics*, **2017**, 49, 1767-1778	36.3	186
152	The OncoArray Consortium: A Network for Understanding the Genetic Architecture of Common Cancers. *Cancer Epidemiology Biomarkers and Prevention*, **2017**, 26, 126-135	4	183
151	Predictive testing for BRCA1/2: attributes, risk perception and management in a multi-centre clinical cohort. *British Journal of Cancer*, **2002**, 86, 1209-16	8.7	163
150	Li-Fraumeni syndrome: cancer risk assessment and clinical management. *Nature Reviews Clinical Oncology*, **2014**, 11, 260-71	19.4	162
149	The genetic epidemiology of prostate cancer and its clinical implications. *Nature Reviews Urology*, **2014**, 11, 18-31	5.5	162
148	Targeted prostate cancer screening in BRCA1 and BRCA2 mutation carriers: results from the initial screening round of the IMPACT study. *European Urology*, **2014**, 66, 489-99	10.2	156
147	Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019. *European Urology*, **2020**, 77, 508-547	10.2	155
146	Juggling roles and expectations: dilemmas faced by women talking to relatives about cancer and genetic testing. *Psychology and Health*, **2004**, 19, 439-455	2.9	146
145	Head and neck sarcomas: prognostic factors and implications for treatment. *British Journal of Cancer*, **1993**, 68, 201-7	8.7	145
144	Mutational spectrum in a worldwide study of 29,700 families with BRCA1 or BRCA2 mutations. *Human Mutation*, **2018**, 39, 593-620	4.7	138

143	Global patterns of prostate cancer incidence, aggressiveness, and mortality in men of african descent. *Prostate Cancer*, **2013**, 2013, 560857	1.9	136
142	Multiple novel prostate cancer predisposition loci confirmed by an international study: the PRACTICAL Consortium. *Cancer Epidemiology Biomarkers and Prevention*, **2008**, 17, 2052-61	4	134
141	Comprehensive functional annotation of 77 prostate cancer risk loci. *PLoS Genetics*, **2014**, 10, e1004102	6	132
140	Identification of nine new susceptibility loci for testicular cancer, including variants near DAZL and PRDM14. *Nature Genetics*, **2013**, 45, 686-9	36.3	128
139	Polygenic susceptibility to prostate and breast cancer: implications for personalised screening. *British Journal of Cancer*, **2011**, 104, 1656-63	8.7	127
138	PALB2, CHEK2 and ATM rare variants and cancer risk: data from COGS. *Journal of Medical Genetics*, **2016**, 53, 800-811	5.8	121
137	Sequencing of prostate cancers identifies new cancer genes, routes of progression and drug targets. *Nature Genetics*, **2018**, 50, 682-692	36.3	112
136	A meta-analysis of genome-wide association studies to identify prostate cancer susceptibility loci associated with aggressive and non-aggressive disease. *Human Molecular Genetics*, **2013**, 22, 408-15	5.6	109
135	Baseline Surveillance in Li-Fraumeni Syndrome Using Whole-Body Magnetic Resonance Imaging: A Meta-analysis. *JAMA Oncology*, **2017**, 3, 1634-1639	13.4	107
134	Genome-Wide Meta-Analyses of Breast, Ovarian, and Prostate Cancer Association Studies Identify Multiple New Susceptibility Loci Shared by at Least Two Cancer Types. *Cancer Discovery*, **2016**, 6, 1052-67	24.4	104
133	Androgen receptor polymorphisms: association with prostate cancer risk, relapse and overall survival. *International Journal of Cancer*, **1999**, 84, 458-65	7.5	100
132	Detection of point mutations in the p53 gene: comparison of single-strand conformation polymorphism, constant denaturant gel electrophoresis, and hydroxylamine and osmium tetroxide techniques. *Human Mutation*, **1993**, 2, 58-66	4.7	92
131	Communication about genetic testing in families of male BRCA1/2 carriers and non-carriers: patterns, priorities and problems. *Clinical Genetics*, **2005**, 67, 492-502	4	91
130	Identification of 19 new risk loci and potential regulatory mechanisms influencing susceptibility to testicular germ cell tumor. *Nature Genetics*, **2017**, 49, 1133-1140	36.3	89
129	Fine-mapping identifies multiple prostate cancer risk loci at 5p15, one of which associates with TERT expression. *Human Molecular Genetics*, **2013**, 22, 2520-8	5.6	88
128	Polygenic hazard score to guide screening for aggressive prostate cancer: development and validation in large scale cohorts. *BMJ, The*, **2018**, 360, j5757	5.9	85
127	The role of BRCA1 and BRCA2 in prostate cancer. *Asian Journal of Andrology*, **2012**, 14, 409-14	2.8	85
126	Germ-line mutations in mismatch repair genes associated with prostate cancer. *Cancer Epidemiology Biomarkers and Prevention*, **2009**, 18, 2460-7	4	84

125	Frequent germline deleterious mutations in DNA repair genes in familial prostate cancer cases are associated with advanced disease. *British Journal of Cancer*, **2014**, 110, 1663-72	8.7	83
124	Association analyses identify 31 new risk loci for colorectal cancer susceptibility. *Nature Communications*, **2019**, 10, 2154	17.4	81
123	Interim Results from the IMPACT Study: Evidence for Prostate-specific Antigen Screening in BRCA2 Mutation Carriers. *European Urology*, **2019**, 76, 831-842	10.2	78
122	Adjuvant Hormone Therapy May Improve Survival in Epithelial Ovarian Cancer: Results of the AHT Randomized Trial. *Journal of Clinical Oncology*, **2015**, 33, 4138-44	2.2	78
121	Targeted prostate cancer screening in men with mutations in BRCA1 and BRCA2 detects aggressive prostate cancer: preliminary analysis of the results of the IMPACT study. *BJU International*, **2011**, 107, 28-39	5.6	76
120	A Review of Prostate Cancer Genome-Wide Association Studies (GWAS). *Cancer Epidemiology Biomarkers and Prevention*, **2018**, 27, 845-857	4	73
119	Allelic imbalance, including deletion of PTEN/MMACI, at the Cowden disease locus on 10q22-23, in hamartomas from patients with Cowden syndrome and germline PTEN mutation. *Genes Chromosomes and Cancer*, **1998**, 21, 61-9	5	71
118	Implications of polygenic risk-stratified screening for prostate cancer on overdiagnosis. *Genetics in Medicine*, **2015**, 17, 789-95	8.1	70
117	The rs10993994 risk allele for prostate cancer results in clinically relevant changes in microseminoprotein-beta expression in tissue and urine. *PLoS ONE*, **2010**, 5, e13363	3.7	68
116	Prevalence of the HOXB13 G84E germline mutation in British men and correlation with prostate cancer risk, tumour characteristics and clinical outcomes. *Annals of Oncology*, **2015**, 26, 756-761	10.3	67
115	Too much, too soon? Patients and health professionalsQviews concerning the impact of genetic testing at the time of breast cancer diagnosis in women under the age of 40. *European Journal of Cancer Care*, **2005**, 14, 272-81	2.4	67
114	Cross-Cancer Genome-Wide Analysis of Lung, Ovary, Breast, Prostate, and Colorectal Cancer Reveals Novel Pleiotropic Associations. *Cancer Research*, **2016**, 76, 5103-14	10.1	66
113	Guilt, blame and responsibility: menG understanding of their role in the transmission of BRCA1/2 mutations within their family. *Sociology of Health and Illness*, **2006**, 28, 969-88	3	65
112	Large-scale transcriptome-wide association study identifies new prostate cancer risk regions. *Nature Communications*, **2018**, 9, 4079	17.4	65
111	MenG decision-making about predictive BRCA1/2 testing: the role of family. *Journal of Genetic Counseling*, **2005**, 14, 207-17	2.5	63
110	Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction. *Nature Genetics*, **2021**, 53, 65-75	36.3	62
109	Male breast cancer in BRCA1 and BRCA2 mutation carriers: pathology data from the Consortium of Investigators of Modifiers of BRCA1/2. *Breast Cancer Research*, **2016**, 18, 15	8.3	58
108	Fine-mapping of prostate cancer susceptibility loci in a large meta-analysis identifies candidate causal variants. *Nature Communications*, **2018**, 9, 2256	17.4	57

107	Identification of multiple risk loci and regulatory mechanisms influencing susceptibility to multiple myeloma. *Nature Communications*, **2018**, 9, 3707	17.4	57
106	Multiple novel prostate cancer susceptibility signals identified by fine-mapping of known risk loci among Europeans. *Human Molecular Genetics*, **2015**, 24, 5589-602	5.6	54
105	Prostate Cancer Risks for Male BRCA1 and BRCA2 Mutation Carriers: A Prospective Cohort Study. *European Urology*, **2020**, 77, 24-35	10.2	53
104	Frequent somatic transfer of mitochondrial DNA into the nuclear genome of human cancer cells. *Genome Research*, **2015**, 25, 814-24	9.7	52
103	Unravelling the genetics of prostate cancer. *American Journal of Medical Genetics Part A*, **2004**, 129C, 65-73		52
102	Generalizability of established prostate cancer risk variants in men of African ancestry. *International Journal of Cancer*, **2015**, 136, 1210-7	7.5	51
101	Genetic predisposition to prostate cancer. *Prostate Cancer and Prostatic Diseases*, **1999**, 2, 9-15	6.2	50
100	Non-Hodgkin© lymphoma presenting with extradural spinal cord compression: functional outcome and survival. *British Journal of Cancer*, **1991**, 63, 126-9	8.7	50
99	A Cross-Cancer Genetic Association Analysis of the DNA Repair and DNA Damage Signaling Pathways for Lung, Ovary, Prostate, Breast, and Colorectal Cancer. *Cancer Epidemiology Biomarkers and Prevention*, **2016**, 25, 193-200	4	47
98	Risk Analysis of Prostate Cancer in PRACTICAL, a Multinational Consortium, Using 25 Known Prostate Cancer Susceptibility Loci. *Cancer Epidemiology Biomarkers and Prevention*, **2015**, 24, 1121-9	4	46
97	Evaluating genetic risk for prostate cancer among Japanese and Latinos. *Cancer Epidemiology Biomarkers and Prevention*, **2012**, 21, 2048-58	4	46
96	Shared heritability and functional enrichment across six solid cancers. *Nature Communications*, **2019** , 10, 431	17.4	45
95	Baseline results from the UK SIGNIFY study: a whole-body MRI screening study in TP53 mutation carriers and matched controls. *Familial Cancer*, **2017**, 16, 433-440	3	39
94	Genome-wide association study identifies susceptibility loci for B-cell childhood acute lymphoblastic leukemia. *Nature Communications*, **2018**, 9, 1340	17.4	39
93	Two Novel Susceptibility Loci for Prostate Cancer in Men of African Ancestry. *Journal of the National Cancer Institute*, **2017**, 109,	9.7	38
92	Atlas of prostate cancer heritability in European and African-American men pinpoints tissue-specific regulation. *Nature Communications*, **2016**, 7, 10979	17.4	37
91	Rare germ line CHEK2 variants identified in breast cancer families encode proteins that show impaired activation. *Cancer Research*, **2006**, 66, 8966-70	10.1	37
90	Integration of multiethnic fine-mapping and genomic annotation to prioritize candidate functional SNPs at prostate cancer susceptibility regions. *Human Molecular Genetics*, **2015**, 24, 5603-18	5.6	35

89	Assessment of polygenic architecture and risk prediction based on common variants across fourteen cancers. *Nature Communications*, **2020**, 11, 3353	17.4	32
88	Radiogenomics Consortium Genome-Wide Association Study Meta-Analysis of Late Toxicity After Prostate Cancer Radiotherapy. *Journal of the National Cancer Institute*, **2020**, 112, 179-190	9.7	32
87	Identification of four new susceptibility loci for testicular germ cell tumour. *Nature Communications* , **2015**, 6, 8690	17.4	30
86	Fine-mapping the HOXB region detects common variants tagging a rare coding allele: evidence for synthetic association in prostate cancer. *PLoS Genetics*, **2014**, 10, e1004129	6	30
85	Germline variation at 8q24 and prostate cancer risk in men of European ancestry. *Nature Communications*, **2018**, 9, 4616	17.4	30
84	SNPs in the kallikrein gene region associated with prostate cancer risk: true cause or association by design?. *Nature Genetics*, **2008**, 40,	36.3	29
83	Polygenic risk-tailored screening for prostate cancer: A benefit-harm and cost-effectiveness modelling study. *PLoS Medicine*, **2019**, 16, e1002998	11.6	29
82	Clinical implications of family history of prostate cancer and genetic risk single nucleotide polymorphism (SNP) profiles in an active surveillance cohort. *BJU International*, **2013**, 112, 666-73	5.6	28
81	Germline DNA Repair Gene Mutations in Young-onset Prostate Cancer Cases in the UK: Evidence for a More Extensive Genetic Panel. *European Urology*, **2019**, 76, 329-337	10.2	28
80	Genome-wide association of familial prostate cancer cases identifies evidence for a rare segregating haplotype at 8q24.21. *Human Genetics*, **2016**, 135, 923-38	6.3	27
79	Rare germline variants in DNA repair genes and the angiogenesis pathway predispose prostate cancer patients to develop metastatic disease. *British Journal of Cancer*, **2018**, 119, 96-104	8.7	27
78	Immunohistochemical expression of BRCA2 protein and allelic loss at the BRCA2 locus in prostate cancer. CRC/BPG UK Familial Prostate Cancer Study Collaborators. *International Journal of Cancer*, **1998**, 78, 1-7	7.5	27
77	Multi-stage genome-wide association study identifies new susceptibility locus for testicular germ cell tumour on chromosome 3q25. *Human Molecular Genetics*, **2015**, 24, 1169-76	5.6	26
76	Quantifying the Genetic Correlation between Multiple Cancer Types. *Cancer Epidemiology Biomarkers and Prevention*, **2017**, 26, 1427-1435	4	25
75	Genome-wide association study of classical Hodgkin lymphoma identifies key regulators of disease susceptibility. *Nature Communications*, **2017**, 8, 1892	17.4	24
74	The PROFILE Feasibility Study: Targeted Screening of Men With a Family History of Prostate Cancer. *Oncologist*, **2016**, 21, 716-22	5.7	24
73	Circulating vitamin D concentrations and risk of breast and prostate cancer: a Mendelian randomization study. *International Journal of Epidemiology*, **2019**, 48, 1416-1424	7.8	24
72	Identification of Novel Susceptibility Loci and Genes for Prostate Cancer Risk: A Transcriptome-Wide Association Study in Over 140,000 European Descendants. *Cancer Research*, **2019**, 79, 3192-3204	10.1	23

71	Association of Genomic Domains in and with Prostate Cancer Risk and Aggressiveness. *Cancer Research*, **2020**, 80, 624-638	10.1	22
70	Reducing overdiagnosis by polygenic risk-stratified screening: findings from the Finnish section of the ERSPC. *British Journal of Cancer*, **2015**, 113, 1086-93	8.7	21
69	Appraising the relevance of DNA copy number loss and gain in prostate cancer using whole genome DNA sequence data. *PLoS Genetics*, **2017**, 13, e1007001	6	20
68	DESNT: A Poor Prognosis Category of Human Prostate Cancer. *European Urology Focus*, **2018**, 4, 842-850	5.1	18
67	The psychological impact of undergoing genetic-risk profiling in men with a family history of prostate cancer. *Psycho-Oncology*, **2015**, 24, 1492-9	3.9	17
66	A genetic study and meta-analysis of the genetic predisposition of prostate cancer in a Chinese population. *Oncotarget*, **2016**, 7, 21393-403	3.3	17
65	An original phylogenetic approach identified mitochondrial haplogroup T1a1 as inversely associated with breast cancer risk in BRCA2 mutation carriers. *Breast Cancer Research*, **2015**, 17, 61	8.3	16
64	Homeobox B13 G84E Mutation and Prostate Cancer Risk. *European Urology*, **2019**, 75, 834-845	10.2	16
63	A Genetic Risk Score to Personalize Prostate Cancer Screening, Applied to Population Data. *Cancer Epidemiology Biomarkers and Prevention*, **2020**, 29, 1731-1738	4	14
62	"It's all very well reading the letters in the genome, but it's a long way to being able to write": Men's interpretations of undergoing genetic profiling to determine future risk of prostate cancer. *Familial Cancer*, **2014**, 13, 625-35	3	14
61	Delivering cancer genetics services--new ways of working. *Familial Cancer*, **2007**, 6, 163-7	3	14
60	An improved high throughput heteroduplex mutation detection system for screening BRCA2 mutations-fluorescent mutation detection (F-MD). *Human Mutation*, **2001**, 17, 220-32	4.7	14
59	Polygenic hazard score is associated with prostate cancer in multi-ethnic populations. *Nature Communications*, **2021**, 12, 1236	17.4	14
58	Men with a susceptibility to prostate cancer and the role of genetic based screening. *Translational Andrology and Urology*, **2018**, 7, 61-69	2.3	14
57	A Germline Variant at 8q24 Contributes to Familial Clustering of Prostate Cancer in Men of African Ancestry. *European Urology*, **2020**, 78, 316-320	10.2	13
56	Large-scale Analysis Demonstrates Familial Testicular Cancer to have Polygenic Aetiology. *European Urology*, **2018**, 74, 248-252	10.2	13
55	Multicentric breast cancer: clonality and prognostic studies. *Breast Cancer Research and Treatment*, **2011**, 129, 703-16	4.4	12
54	An integrative multi-omics analysis to identify candidate DNA methylation biomarkers related to prostate cancer risk. *Nature Communications*, **2020**, 11, 3905	17.4	12

53	Rare Germline Variants in ATM Predispose to Prostate Cancer: A PRACTICAL Consortium Study. *European Urology Oncology*, **2021**, 4, 570-579	6.7	12
52	Identification of shared and unique susceptibility pathways among cancers of the lung, breast, and prostate from genome-wide association studies and tissue-specific protein interactions. *Human Molecular Genetics*, **2015**, 24, 7406-20	5.6	11
51	FRMD6 has tumor suppressor functions in prostate cancer. *Oncogene*, **2021**, 40, 763-776	9.2	11
50	Patterns of recurrence after prostate bed radiotherapy. *Radiotherapy and Oncology*, **2019**, 141, 174-180	5.3	10
49	LocusExplorer: a user-friendly tool for integrated visualization of human genetic association data and biological annotations. *Bioinformatics*, **2016**, 32, 949-51	7.2	10
48	Delivery of cancer genetics services: The Royal Marsden telephone clinic model. *Familial Cancer*, **2007**, 6, 213-9	3	10
47	A prospective prostate cancer screening programme for men with pathogenic variants in mismatch repair genes (IMPACT): initial results from an international prospective study. *Lancet Oncology, The*, **2021**, 22, 1618-1631	21.7	10
46	Germline genetic profiling in prostate cancer: latest developments and potential clinical applications. *Future Science OA*, **2016**, 2, FSO87	2.7	10
45	Genome-wide association study implicates immune dysfunction in the development of Hodgkin lymphoma. *Blood*, **2018**, 132, 2040-2052	2.2	10
44	Analysis of Over 140,000 European Descendants Identifies Genetically Predicted Blood Protein Biomarkers Associated with Prostate Cancer Risk. *Cancer Research*, **2019**, 79, 4592-4598	10.1	9
43	Ambiguity in a masculine world: Being a BRCA1/2 mutation carrier and a man with prostate cancer. *Psycho-Oncology*, **2017**, 26, 1987-1993	3.9	9
42	Two-stage Study of Familial Prostate Cancer by Whole-exome Sequencing and Custom Capture Identifies 10 Novel Genes Associated with the Risk of Prostate Cancer. *European Urology*, **2021**, 79, 353-361	10.2	9
41	Identification of Germline Genetic Variants that Increase Prostate Cancer Risk and Influence Development of Aggressive Disease. *Cancers*, **2021**, 13,	6.6	8
40	The role of the prostate cancer gene 3 urine test in addition to serum prostate-specific antigen level in prostate cancer screening among breast cancer, early-onset gene mutation carriers. *Urologic Oncology: Seminars and Original Investigations*, **2015**, 33, 202.e19-28	2.8	7
39	Germline variants in IL4, MGMT and AKT1 are associated with prostate cancer-specific mortality: An analysis of 12,082 prostate cancer cases. *Prostate Cancer and Prostatic Diseases*, **2018**, 21, 228-237	6.2	7
38	Psychosocial impact of undergoing prostate cancer screening for men with BRCA1 or BRCA2 mutations. *BJU International*, **2019**, 123, 284-292	5.6	7
37	Common genetic variants associated with disease from genome-wide association studies are mutually exclusive in prostate cancer and rheumatoid arthritis. *BJU International*, **2013**, 111, 1148-55	5.6	7
36	Translating genetic risk factors for prostate cancer to the clinic: 2013 and beyond. *Future Oncology*, **2014**, 10, 1679-94	3.6	7

35	Germline mutations in fumarate hydratase (FH) do not predispose to prostate cancer. *Prostate Cancer and Prostatic Diseases*, **2003**, 6, 12-4	6.2	7
34	African-specific improvement of a polygenic hazard score for age at diagnosis of prostate cancer. *International Journal of Cancer*, **2021**, 148, 99-105	7.5	7
33	Combined Effect of a Polygenic Risk Score and Rare Genetic Variants on Prostate Cancer Risk. *European Urology*, **2021**, 80, 134-138	10.2	7
32	Diffusion-weighted MRI for detecting prostate tumour in men at increased genetic risk. *European Journal of Radiology Open*, **2014**, 1, 22-27	2.6	6
31	Genetic testing for BRCA1: effects of a randomised study of knowledge provision on interest in testing and long term test uptake; implications for the NICE guidelines. *Familial Cancer*, **2009**, 8, 5-13	3	6
30	Validation of loci at 2q14.2 and 15q21.3 as risk factors for testicular cancer. *Oncotarget*, **2018**, 9, 12630-12638	5.5	6
29	Diagnosis and Management of Hereditary Carcinoids. *Recent Results in Cancer Research*, **2016**, 205, 149-68	3.5	6
28	Genetic predisposition to prostate cancer: an update. *Familial Cancer*, **2021**, 1	3	6
27	Practical considerations for optimising homologous recombination repair mutation testing in patients with metastatic prostate cancer. *Journal of Pathology: Clinical Research*, **2021**, 7, 311-325	5.3	6
26	The effect of sample size on polygenic hazard models for prostate cancer. *European Journal of Human Genetics*, **2020**, 28, 1467-1475	5.3	5
25	Height, selected genetic markers and prostate cancer risk: results from the PRACTICAL consortium. *British Journal of Cancer*, **2017**, 117, 734-743	8.7	5
24	The clinical genetics of prostate cancer. *Hereditary Cancer in Clinical Practice*, **2004**, 2, 111-21	2.3	5
23	Germline genetic variation in prostate susceptibility does not predict outcomes in the chemoprevention trials PCPT and SELECT. *Prostate Cancer and Prostatic Diseases*, **2020**, 23, 333-342	6.2	5
22	The Variant C.349A>G Is Associated with Prostate Cancer Risk and Carriers Share a Common Ancestor. *Cancers*, **2020**, 12,	6.6	4
21	Prostate cancer genome-wide association study from 89,000 men using the OncoArray chip to identify novel prostate cancer susceptibility loci.. *Journal of Clinical Oncology*, **2016**, 34, 1525-1525	2.2	4
20	Oncologically Relevant Findings Reporting and Data System (ONCO-RADS): Guidelines for the Acquisition, Interpretation, and Reporting of Whole-Body MRI for Cancer Screening. *Radiology*, **2021**, 299, 494-507	20.5	4
19	The BARCODE1 Pilot: a feasibility study of using germline single nucleotide polymorphisms to target prostate cancer screening. *BJU International*, **2021**,	5.6	4
18	Runs of homozygosity and testicular cancer risk. *Andrology*, **2019**, 7, 555-564	4.2	3

17	KLK3 SNP-SNP interactions for prediction of prostate cancer aggressiveness. *Scientific Reports*, **2021**, 11, 9264	4.9	3
16	Post hoc Analysis for Detecting Individual Rare Variant Risk Associations Using Probit Regression Bayesian Variable Selection Methods in Case-Control Sequencing Studies. *Genetic Epidemiology*, **2016**, 40, 461-9	2.6	3
15	seXY: a tool for sex inference from genotype arrays. *Bioinformatics*, **2017**, 33, 561-563	7.2	3
14	Additional SNPs improve risk stratification of a polygenic hazard score for prostate cancer. *Prostate Cancer and Prostatic Diseases*, **2021**, 24, 532-541	6.2	3
13	Breast and Prostate Cancer Risks for Male BRCA1 and BRCA2 Pathogenic Variant Carriers Using Polygenic Risk Scores. *Journal of the National Cancer Institute*, **2021**,	9.7	3
12	Prostate Cancer Risk by BRCA2 Genomic Regions. *European Urology*, **2020**, 78, 494-497	10.2	2
11	Baseline and post prophylactic tubal-ovarian surgery CA125 levels in BRCA1 and BRCA2 mutation carriers. *Familial Cancer*, **2014**, 13, 197-203	3	2
10	Updates in Prostate Cancer Research and Screening in Men at Genetically Higher Risk. *Current Genetic Medicine Reports*, **2021**, 9, 47-58	2.2	2
9	Marital status and prostate cancer incidence: a pooled analysis of 12 case-control studies from the PRACTICAL consortium. *European Journal of Epidemiology*, **2021**, 36, 913-925	12.1	2
8	RAZOR: A Phase II Open Randomized Trial of Screening Plus Goserelin and Raloxifene Versus Screening Alone in Premenopausal Women at Increased Risk of Breast Cancer. *Cancer Epidemiology Biomarkers and Prevention*, **2018**, 27, 58-66	4	2
7	African-specific improvement of a polygenic hazard score for age at diagnosis of prostate cancer		1
6	Assessment of Polygenic Architecture and Risk Prediction based on Common Variants Across Fourteen Cancers		1
5	Immunohistochemical expression of BRCA2 protein and allelic loss at the BRCA2 locus in prostate cancer **1998**, 78, 1		1
4	Prostate cancer risk in men of differing genetic ancestry and approaches to disease screening and management in these groups.. *British Journal of Cancer*, **2021**,	8.7	1
3	Genetics of prostate cancer and its utility in treatment and screening. *Advances in Genetics*, **2021**, 108, 147-199	3.3	0
2	P386: Screening for endometrial cancer in a high-risk population (Hereditary Non Polyposis Colorectal Cancer) pilot study. *Ultrasound in Obstetrics and Gynecology*, **2003**, 22, 174-174	5.8	
1	The genetics of breast cancer. *The Journal of the British Menopause Society*, **2002**, 8, 24-29		